ABT-737 reportedly antagonizes Bcl-2, Mcl-1 and Bcl-XL, suggesting the effects of BH3 mimetics could overcome EGFR-TKI resistance in NSCLC containing EGFR-mutant and harboring the BIM deletion polymorphism. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.